

PACO20072

Product Information

Size:

50ul

Reactivity:

Human

Source:

Rabbit

Isotype:

IgG

Applications:

ELISA, WB, IHC

Recommended dilutions:

ELISA:1:1000-1:2000, WB:1:200-1:1000,
IHC:1:50-1:200

Protein Background:

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation.

Gene ID:

NDUFA8

Uniprot

P51970

Synonyms:

NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa


Immunogen:

Synthetic peptide of human NDUFA8.

Storage:

-20° C, pH7.4 PBS, 0.05% NaN₃, 40% Glycerol


Product Images



The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using PACO20072(NDUFA8 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).



Gel: 10%SDS-PAGE, Lysate: 40 ug, Lane: 293T cells, Primary antibody: PACO20072(NDUFA8 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes.



The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using PACO20072(NDUFA8 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).